Priority Date: 24.02.12 (KR 20120019221)

MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME

  • Application ID: EP13752075
  • Status: EXAMINATION IN PROGRESS

Attorney

operating since 1974
Headquarter in Munich
active in Legal Services and IP Consulting

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY) is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 189 others are specialized in all of these IPC classes. For a similar patent, they might be a good choice.

Timeline

  • 24.02.2012 - Priority Date (KR 20120019221)
  • 29.08.2013 - Publication A1 (WO2013125891)
  • 31.12.2014 - Publication A1 (EP2818480)